Floatz logo

es101

Thoracic Tumors

Elpiscience Biopharma, Ltd.monoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Thoracic Tumors cohort.

Asset / SponsorPhaseRating
Carboplatin
Fundación GECP
Phase 3BB
Pralsetinib, trans-
Hoffmann-La Roche
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Nanfang Hospital, Southern Medical University
Phase 3B
Gefetinib
Chinese Society of Lung Cancer
Phase 3B
Pembrolizumab
Amgen
Phase 3B

View all 24 →

Same molecule, other indications

es101 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
cancerDormant
CC
Indicative ·
41 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →